Lenalidomide Combined to Azacitidine in Intermediate-2 or High Risk MDS With Del 5q
NCT ID: NCT01088373
Last Updated: 2017-12-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
50 participants
INTERVENTIONAL
2010-03-25
2016-07-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Overall, the combination of Lenalidomide and Azacitidine is well-tolerated and early results suggest some efficacy in advanced MDS without del 5q.
In this trial, we will combine Lenalidomide to Azacytidine in higher risk MDS with del (5q).
Patients will receive azacitidine( 75mg/m2/day for 5 days every 28 days) combined to escalating doses of lenalidomide (starting at relatively low dose).
For patients in hematological CR, PR, HI or marrow CR after cycle 2 or 4, it is mandatory to continue on Azacitidine + Lenalidomide as long as there is no unacceptable toxicity or overt progression, with the schedule that yielded response.
In patient still responding after 52 weeks, the drug will continue to be supplied, and follow up until death will be continued in all patients.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Azacitidine, Lenalidomide
Azacitidine combined to Lenalidomide
Azacitidine: 75mg/m2/d for 5 days per cycle of 28 days. Lenalidomide: 5mg/day during 14 days for cohort 1. Lenalidomide: 5mg/day during 21 days for cohort 2. Lenalidomide: 10mg/day during 21 days for cohort 3.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Azacitidine combined to Lenalidomide
Azacitidine: 75mg/m2/d for 5 days per cycle of 28 days. Lenalidomide: 5mg/day during 14 days for cohort 1. Lenalidomide: 5mg/day during 21 days for cohort 2. Lenalidomide: 10mg/day during 21 days for cohort 3.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. must understand and voluntarily sign an informed consent form.
3. patient considered ineligible for intensive chemotherapy due to age, cardiac contraindication to anthracyclines, comorbidities, previous failure of intensive chemotherapy, or patient willing to avoid intensive chemotherapy.
4. must be able to adhere to the study visit schedule and other protocol requirements.
5. prior thalidomide allowed.
6. documented diagnosis of MDS (according to FAB definition, ie. with marrow blasts up to 30%, or CMML with WBC \< 13000/mm3 that meets IPSS criteria for intermediate-2 or high-risk disease.
7. with an associated del 5q\[31\](the deleted chromosomal region must include 5q\[31\]), with or without additional cytogenetic abnormalities.
8. female subjects of childbearing potential must:
* understand the study drug is expected to have a teratogenic risk.
* agree to have a medically supervised pregnancy test with a minimum sensitivity of 25mIU/ml on the day of the study visit or in the 3 days prior to the study visit once the subject has been on effective contraception for at least weeks. This requirement also applies to women of childbearing potential who practice complete and continued abstinence. the test should ensure the subject is not pregnant when she starts treatment.
* agree to have a medically supervised pregnancy test every 4 weeks including 4 weeks after the end of study treatment, except in the case of confirmed tubal sterilization. these pregnancy tests should be performed on the day of the study visit or in the 3 days prior to the study visit.
this requirement also applies to women of childbearing potential who practice complete and continued abstinence.
\* agree to use, and to be able to comply with effective contraception without interruption, 4 weeks before starting study drug throughout the entire duration study drug therapy(including doses interruptions)and for 3 months after the end of the study drug therapy even if she has amenorrhea this applies unless the subject commits to absolute and continuous abstinence confirmed on a monthly basis, to avoid pregnancy for the duration of study.
the following are effective methods of contraception:
* implant
* levonorgestrel-releasing intrauterine system(IUS)
* Medroxyprogesterone acetate depot, tubal sterilization.
* sexual intercourse with a vasectomised male partner only(vasectomised must be confirmed by two negative semen analyses), ovulation inhibitory progesterone-only pills(i.e.desogestrel).
if not established on effective contraception, the female subject must be referred to an appropriately trained health care professional for contraceptive advice in order that contraception can be initiated.
Because of the increased risk of venous thromboembolism in patients with multiple myeloma taking lenalidomide and dexamethasone, combined oral contraceptive pills are not recommended. If a female subject is currently using combined oral contraception, the patient should switch to one of the effective methods listed above. The risk of venous thromboembolism continues for 4 to 6 weeks after discontinuing combined oral contraception. The efficacy of contraceptive steroids may be reduced during co-treatment with dexamethasone.
Implants and levonorgestrel-releasing intrauterine systems are associated with an increased risk of infection at the time of insertion and irregular vaginal bleeding. Prophylactic antibiotics should be considered particularly in patients with neutropenia .
Copper-releasing intrauterine devices are generally not recommended due to the potential risks of infection at the time of insertion and menstrual blood loss which may compromise patients with neutropenia or thrombocytopenia.
* Understand that even if she has amenorrhea, she must follow all the advice on effective contraception.
* She understands the potential consequences of pregnancy and the need to rapidly consult if there is a risk of pregnancy
9. Male patients must :
* Agree the need for the use of a condom if engaged in sexual activity with a woman of childbearing potential. during the entire period of treatment, even if disruption of treatment and during 3 months after end of treatment
* Agree not to conceive during treatment and study drug therapy (including doses interruptions) and for 3 months after the end of the study drug therapy
* Agree not to donate semen during study drug therapy and for one week after end of study drug therapy.
* Agree to learn about the procedures for preservation of sperm., before starting treatment
10. All subjects must :
* Agree to abstain from donating blood while taking study drug therapy and for one week following discontinuation of study drug therapy.
* Agree not to share study medication with another person and to return all unused study drug to the investigator.
11. Signed informed consent prior to start of any study-specific procedures,
12. Ability to participate to a clinical trial and adhere to study procedures.
* Criteria for women of non-childbearing potential :
A female patient or a female partner of a male patient is considered to have childbearing potential unless she meets at least one of the following criteria:
* Age ≥ 50 years and naturally amenorrhoeic for ≥ 1 year (amenorrhoea following cancer therapy does not rule out childbearing potential)
* Premature ovarian failure confirmed by a specialist gynaecologist
* Previous bilateral salpingo-oophorectomy, or hysterectomy
* XY genotype, Turner syndrome, uterine agenesis.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Celgene
INDUSTRY
Groupe Francophone des Myelodysplasies
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lionel ADES, MD
Role: PRINCIPAL_INVESTIGATOR
GFM
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital kremlin Bicêtre
Le Kremlin-Bicêtre, IDF, France
Chu Brabois
Nancy, Vandoeuvre, France
CHU d'Amiens
Amiens, , France
CHU Angers
Angers, , France
Hôpital de la cote basque
Bayonne, , France
Hôpital Avicenne
Bobigny, , France
CHU Haut-Lévèque
Bordeaux, , France
CH René Dubos
Cergy-Pontoise, , France
CHU de
Clermont-Ferrand, , France
Centre Hospitalier Sud-Francilien
Corbeil-Essonnes, , France
CHU Henri Mondor
Créteil, , France
CHU de Grenoble
Grenoble, , France
CH Le mans
Le Mans, , France
Centre Hospitalier de Lens
Lens, , France
CHRU de Limoges
Limoges, , France
Hôpital Edouard Heriot, dpt Hématologie Clinique
Lyon, , France
Institut Paoli-Calmette, Département d'hématologie
Marseille, , France
Centre Hospitalier de Meaux
Meaux, , France
Hopital de l'Hotel Dieu, Hematology Dpt
Nantes, , France
CHU Archet
Nice, , France
CHR La Source orléans
Orléans, , France
Hôpital Saint Louis
Paris, , France
Saint-Louis Hospital
Paris, , France
Hôpital Saint-Antoine
Paris, , France
Hôpital la pitié-Salpétrière
Paris, , France
Hopital Cochin Service d'Hématologie
Paris, , France
Hôpital Maréchal Joffre
Perpignan, , France
Hôpital Jean-Bernard
Poitiers, , France
centre hospitalier Jacques Puel
Rodez, , France
Hôpital Henri Becquerel
Rouen, , France
Hôpital Purpan, médecine Interne
Toulouse, , France
Hôpital PURPAN, Service d'Hématologie Clinique
Toulouse, , France
CHU Bretonneau
Tours, , France
Institut gustave Roussy
Villejuif, , France
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Website of the Groupe Francophone des Myélodysplasies (GFM)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AZA-REV-09
Identifier Type: -
Identifier Source: org_study_id